Biogen (NASDAQ:BIIB) Price Target Raised to $237.00

Biogen (NASDAQ:BIIB) had its target price hoisted by stock analysts at HC Wainwright from $228.00 to $237.00 in a report released on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 28.96% from the stock’s previous close.

Several other equities research analysts have also recently commented on the company. TD Cowen lifted their target price on Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Piper Sandler upped their price target on Biogen from $157.00 to $177.00 and gave the company a “neutral” rating in a research note on Monday, February 9th. Barclays assumed coverage on Biogen in a research report on Thursday, February 19th. They issued an “equal weight” rating and a $185.00 price objective for the company. Royal Bank Of Canada boosted their price objective on Biogen from $217.00 to $233.00 and gave the stock an “outperform” rating in a report on Monday, February 9th. Finally, Wolfe Research set a $231.00 target price on shares of Biogen in a research note on Monday, February 9th. Twelve investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $208.31.

Biogen Price Performance

Shares of BIIB stock opened at $183.78 on Thursday. Biogen has a 1 year low of $110.04 and a 1 year high of $202.41. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The firm’s 50 day moving average is $186.41 and its 200-day moving average is $171.07. The firm has a market capitalization of $26.97 billion, a price-to-earnings ratio of 20.86, a PEG ratio of 1.46 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same quarter last year, the business posted $3.44 earnings per share. Biogen’s revenue for the quarter was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Sell-side analysts forecast that Biogen will post 15.83 EPS for the current fiscal year.

Insider Buying and Selling at Biogen

In related news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the transaction, the insider owned 8,043 shares of the company’s stock, valued at $1,607,232.69. This trade represents a 24.85% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.18% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Biogen

Several large investors have recently bought and sold shares of the company. Elevation Point Wealth Partners LLC bought a new position in shares of Biogen during the second quarter worth $25,000. Reflection Asset Management bought a new stake in shares of Biogen in the 4th quarter valued at $25,000. WPG Advisers LLC raised its stake in Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after buying an additional 117 shares during the period. Accredited Wealth Management LLC lifted its holdings in Biogen by 1,233.3% during the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 185 shares in the last quarter. Finally, First Horizon Corp bought a new position in Biogen during the fourth quarter worth about $30,000. Institutional investors own 87.93% of the company’s stock.

Key Stories Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash, bringing SYFOVRE and EMPAVELI into Biogen’s commercial portfolio and accelerating its push into immunology and nephrology — a clear strategic rationale for near‑term revenue lift and diversification. Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion
• Positive Sentiment: Multiple analysts raised price targets and maintained favorable verdicts (Oppenheimer, Canaccord and others increased PTs substantially), supporting upside narrative and investor sentiment around Biogen’s growth prospects post‑deal. Wedbush Raises Price Target on Biogen
• Positive Sentiment: Regulatory/clinical tailwinds: the FDA cleared a higher‑dose Spinraza regimen (SMA), which supports Biogen’s near‑term revenue profile and competitive positioning in neurological rare diseases. Biogen Secures FDA Nod for Higher Dose of Spinraza
• Neutral Sentiment: Biogen management says the combined cash flow from Biogen + Apellis will improve leverage and free capacity for additional strategic deals — a constructive medium‑term message but contingent on integration execution. Biogen Turns Its Sights to Early‑Stage Assets — CFO Interview
• Neutral Sentiment: Sector M&A remains active (other large pharma deals announced), which generally supports valuations for strategic acquirers but also raises competition for assets and deal multiples. Lilly to Buy Centessa for $7.8B
• Neutral Sentiment: Some sell‑side analysts and investors are tempering expectations for Apellis standalone upside now that a deal is announced (J.P. Morgan maintained a Hold on APLS), which is relevant to how the market prices the acquisition premium. Hold Rating on Apellis Reflects Biogen Takeover Cap
• Negative Sentiment: Deal financing and cash use: investors pushed back initially because the $5.6B is cash‑funded (plus contingent value rights), which can press near‑term free cash and led to a pullback in BIIB shares when the deal was announced. Why Biogen Stock Sank While the Market Soared
• Negative Sentiment: Investor litigation/investigation: a law firm announced an inquiry into the adequacy of the Apellis sale price/process, which adds legal/PR risk and could complicate closing or create distractions. Apellis Investor Alert — Investigation Announced

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.